Clinical trials: Hemostasis Change
Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma
Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma
This clinical trial studies genetically modified peripheral blood stem cell transplant in treating patients with HIV-associated non-Hodgkin or Hodgkin lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma, AIDS-related Diffuse Small Cleaved Cell Lymphoma
- Trial name
- NCT01769911
- Testing
- carmustine, cytarabine, melphalan
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Cancer Prevention, Weight Loss
PROFAST Intervention in Precursor Multiple Myeloma
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)…
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS
- Trial name
- PROFAST (NCT05565638)
- Testing
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have…
- Conditions
- Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, Multiple Myeloma
- Trial name
- NCT06357754
- Testing
- Idecabtagene vicleucel, Lisocabtagene maraleucel
- Where
- 8 sites in United States, Germany and 2 more
- Volunteers
- 50 people
- Sponsor
- Bristol-Myers Squibb
Avascular Necrosis of Hip, Total Hip Replacement Arthroplasty
Rotational Thromboelstometry (ROTEM) change_colloid_total Hip Replacement Arthroplasty
The investigators administered different kinds of colloids before transfusion of red blood cell to patient undergoing total hip replacement arthroplasty.
- Trial name
- NCT01512628
- Testing
- Pentaspan, voluven, volulyte
- Where
- South Korea
- Volunteers
- 75 people
- Sponsor
- Seoul National University Bundang Hospital
Patients Receiving Direct Oral Anticoagulants
Effect of Tranexamic Acid-Modified Leukocyte- and Platelet-Rich Fibrin on Hemostasis and Wound Healing After Tooth Extraction in Patients Receiving Direct Oral Anticoagulants
This randomized split-mouth clinical study evaluated the effects of tranexamic acid-modified leukocyte- and platelet-rich fibrin (L-PRF) on hemostasis, postoperative pain, and soft-tissue wound healing after tooth extraction in…
- Trial name
- NCT07830875
- Testing
- Tranexamic Acid-Modified L-PRF, Absorbable Gelatin Sponge
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- Cumhuriyet University
Multiple Myeloma, Primary Plasma Cell Leukemia
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.
- Trial name
- NCT06333509
- Testing
- CT071
- Volunteers
- 166 people
- Sponsor
- CARsgen Therapeutics Co., Ltd.
Multiple Myeloma
Serum Free Light Change in Multiple Myeloma
The purpose of this study is to evaluate the predictive role of free Kappa/Lambda ration in Multiple Myeloma post-transplant.
- Trial name
- NCT00910078
- Where
- Italy
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
This phase II MATCH treatment trial identifies the effects of ado-trastuzumab emtansine in patients whose cancer has a genetic change called HER2 amplification.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439110
- Testing
- Trastuzumab Emtansine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Hypothermia, Burns
Thermogard™ Efficacy Trial
The purpose of this study is to determine if the Thermogard™ central venous catheter can prevent hypothermia (defined as a core body temperature less then 36.0 °C) in severely burned patients who are undergoing surgery for…
- Trial name
- NCT00822796
- Testing
- Thermogard™, Standard central venous catheter
- Volunteers
- 9 people
- Sponsor
- Brooke Army Medical Center
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
This phase II MATCH treatment trial tests how well BVD-523FB (ulixertinib) works in treating patients with cancer that has certain genetic changes.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06400225
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Shift-Work Related Sleep Disturbance, Inflammation
Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
The goal of this observational study is to learn if acutely and/or chronically altered sleep induces inflammation and/or a pro-thrombotic state (a tendency to form clots) in hospital workers who either work in shifts or are…
- Conditions
- Shift-Work Related Sleep Disturbance, Inflammation, Hemostatic Disorder, Sleep Disorder
- Trial name
- IPNO (NCT05775731)
- Testing
- Tests for markers of inflammation and activated hemostasis
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centro Cardiologico Monzino
Abortion Early, Abortion, Complete
Clotting Parameters After Medical Abortion
Venous thromboembolism (VTE - blood clots that form in deep veins or in the lungs) has been identified as a leading cause of death in economically developed countries for pregnant and recently-pregnant women.
- Conditions
- Abortion Early, Abortion, Complete, Abortion, Second Trimester, Termination of Pregnancy Complicated by Embolism
- Trial name
- C-PLAN (NCT04824118)
- Testing
- Thromboelastometry, Clotting Studies, Full Blood Count
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- NHS Lothian
Relapsed/Refractory Multiple Myeloma
A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan
Multiple myeloma (MM) is an incurable disease characterized by the growth of monoclonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease state of etentamig in adult…
- Trial name
- NCT05286229
- Testing
- Etentamig
- Where
- 6 sites in Japan
- Volunteers
- 8 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
This Phase I clinical trial is evaluating chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells) which recognize NKG2D-ligands on the surface of cancer cells.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Multiple Myeloma
- Trial name
- NCT02203825
- Testing
- CM-CS1 T-cell infusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Celyad Oncology SA
Previously Untreated Symptomatic Multiple Myeloma
Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance
The investigators propose this study utilizing Lenalidomide, Adriamycin, Dexamethasone (RAD) as comparator arm for Lenalidomide, Bortezomib, Dexamethasone (VRD) with the latter being considered a novel "standard" as an induction…
- Trial name
- NCT01685814
- Testing
- Lenalidomide, Bortezomib, autologous stem cell transplant, allogeneic stem cell transplant
- Where
- 32 sites in Germany
- Volunteers
- 406 people
- Sponsor
- Wuerzburg University Hospital
Intracerebral Hemorrhage, Hemorrhagic Risk Conditions
Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator for Intracerebral Hemorrhage
Intracerebral hemorrhage (ICH) is associated with high mortality and long-term disability, and effective treatment options remain limited.
- Conditions
- Intracerebral Hemorrhage, Hemorrhagic Risk Conditions, Bleeding Disorders
- Trial name
- MIMICK-TIPITCH (NCT07411079)
- Testing
- Ex vivo exposure to modified rtPA
- Where
- France
- Volunteers
- 1,126 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Postoperative Morbidity, Postoperative Mortality
Hemostasis Evolution During Fluid Loading in Abdominal Surgery. Effects of Fluid Choice: Saline Versus Hydroxyethyl Starch (HAEMO Study)
The primary purpose of the study is to evaluate whether the type of fluid (0.9% saline or 6% Hydroxyethyl starch 130/0.4) in the context of an individualized goal-directed fluid therapy is associated with a difference in…
- Conditions
- Postoperative Morbidity, Postoperative Mortality, Hemostasis Change
- Trial name
- HAEMO (NCT03420261)
- Testing
- 0.9% saline, HES 130/0.4
- Where
- France
- Volunteers
- 56 people
- Sponsor
- University Hospital, Clermont-Ferrand
Multiple Myeloma
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
The purpose of the study is to determine the best treatment approach based on the risk profile of the cancer cells and on how the disease responds to treatment.
- Trial name
- NCT07624513
- Testing
- Isatuximab, Iberdomide, Bortezomib (B)
- Where
- 3 sites in United States
- Volunteers
- 720 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
This phase II MATCH treatment trial tests how well MLN0128 (TAK-228) works in treating patients with cancer that has certain genetic changes called TSC1 or TSC2 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390865
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma
The main objective of this study is to evaluate the minimal residual disease-negativity rate after administration of the combination of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab as induction and consolidation therapy…
- Trial name
- IFM2018-01 (NCT03669445)
- Testing
- Ixazomib, Lenalidomide, Dexamethasone
- Where
- 12 sites in France
- Volunteers
- 45 people
- Sponsor
- University Hospital, Toulouse